Cyclacel Pharmaceuticals Inc (CYCC)
1.59
-0.07
(-4.36%)
USD |
NASDAQ |
Jun 25, 16:00
1.58
-0.01
(-0.63%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Research and Development Expense (TTM): 16.28M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 16.28M |
| December 31, 2023 | 19.16M |
| September 30, 2023 | 22.34M |
| June 30, 2023 | 21.52M |
| March 31, 2023 | 20.99M |
| December 31, 2022 | 20.27M |
| September 30, 2022 | 17.62M |
| June 30, 2022 | 17.42M |
| March 31, 2022 | 17.32M |
| December 31, 2021 | 14.93M |
| September 30, 2021 | 12.30M |
| June 30, 2021 | 9.157M |
| March 31, 2021 | 6.219M |
| December 31, 2020 | 4.759M |
| September 30, 2020 | 4.775M |
| June 30, 2020 | 4.763M |
| March 31, 2020 | 4.753M |
| December 31, 2019 | 4.659M |
| September 30, 2019 | 4.37M |
| June 30, 2019 | 4.512M |
| March 31, 2019 | 4.541M |
| December 31, 2018 | 4.327M |
| September 30, 2018 | 3.931M |
| June 30, 2018 | 3.684M |
| March 31, 2018 | 3.724M |
| Date | Value |
|---|---|
| December 31, 2017 | 4.238M |
| September 30, 2017 | 5.424M |
| June 30, 2017 | 6.875M |
| March 31, 2017 | 8.29M |
| December 31, 2016 | 9.477M |
| September 30, 2016 | 10.10M |
| June 30, 2016 | 10.60M |
| March 31, 2016 | 10.54M |
| December 31, 2015 | 12.38M |
| September 30, 2015 | 14.24M |
| June 30, 2015 | 16.31M |
| March 31, 2015 | 18.28M |
| December 31, 2014 | 18.28M |
| September 30, 2014 | 16.35M |
| June 30, 2014 | 15.96M |
| March 31, 2014 | 14.04M |
| December 31, 2013 | 11.28M |
| September 30, 2013 | 10.78M |
| June 30, 2013 | 7.739M |
| March 31, 2013 | 6.825M |
| December 31, 2012 | 6.592M |
| September 30, 2012 | 6.797M |
| June 30, 2012 | 7.331M |
| March 31, 2012 | 7.473M |
| December 31, 2011 | 9.206M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
4.37M
Minimum
Sep 2019
22.34M
Maximum
Sep 2023
12.41M
Average
13.61M
Median
Research and Development Expense (TTM) Benchmarks
| Eliem Therapeutics Inc | 10.78M |
| NovaBay Pharmaceuticals Inc | 0.061M |
| Palatin Technologies Inc | 25.13M |
| iBio Inc | 6.401M |
| Theriva Biologics Inc | 14.79M |